Literature DB >> 28146598

Adherence to Latent Tuberculosis Infection Treatment in a Population with a High Number of Refugee Children.

Tanya Rogo1, Cynthia Eleanya1, Priya Hirway1, Doreen Pelland1, Carol Lewis1, Penelope Dennehy1, Phyllis Losikoff1.   

Abstract

BACKGROUND: Refugee populations in the US have a higher reported prevalence of latent tuberculosis infection (LTBI). The objective of this study was to assess adherence to LTBI treatment in refugee and non-refugee children living in Rhode Island.
METHODS: This was a retrospective review of LTBI patients seen in the Hasbro Pediatric Tuberculosis Clinic between August 2009 and September 2011.
RESULTS: Of 120 patients with LTBI, 93% were foreign-born and 30% were refugees. Overall, 94 children (78.3%) completed therapy. Higher rates of treatment completion were seen among patients who were female, referred within the same hospital system, used an interpreter, and did not report side effects. Refugees attended more scheduled visits compared to non-refugees (p=0.019).
CONCLUSIONS: Overall rates of completion of LTBI treatment were high in this population. Better adherence to clinic visits, likely due to the increased support and care coordination provided to the refugee children, improved treatment completion rates. [Full article available at http://rimed.org/rimedicaljournal-2017-02.asp].

Entities:  

Keywords:  TB prevention; adherence; immigrant; refugee

Mesh:

Substances:

Year:  2017        PMID: 28146598

Source DB:  PubMed          Journal:  R I Med J (2013)        ISSN: 0363-7913


  2 in total

Review 1.  A scoping review of paediatric latent tuberculosis infection care cascades: initial steps are lacking.

Authors:  Jeffrey I Campbell; Thomas J Sandora; Jessica E Haberer
Journal:  BMJ Glob Health       Date:  2021-05

2.  Telehealth Reduces Missed Appointments in Pediatric Patients with Tuberculosis Infection.

Authors:  Angela Zhao; Nirali Butala; Casey Morgan Luc; Richard Feinn; Thomas S Murray
Journal:  Trop Med Infect Dis       Date:  2022-02-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.